PainChek FDA Cleared to Commence Sales in US$100M US Market
| Stock | Painchek Ltd (PCK.ASX) |
|---|---|
| Release Time | 8 Oct 2025, 10:59 a.m. |
| Price Sensitive | Yes |
PainChek Granted FDA Clearance for US$100M US Market
- Landmark FDA De Novo Grant for PainChek's Pain Assessment App
- Establishes PainChek as the first and only regulated medical device for pain assessment in the US
- Initial US$100 million per annum addressable market opportunity in the US aged care market
PainChek Ltd has been granted a De Novo classification by the US Food and Drug Administration (FDA) for its PainChek Adult App, a major milestone that establishes PainChek as the first and only regulated medical device available to assess pain in people who cannot reliably verbalize within the US nursing home and long-term care market. The FDA has also created a new product code 'SGB' to formally recognize PainChek as a unique, first-of-its-kind medical device for pain assessment. PainChek's initial addressable market in US aged care comprises over 3 million long-term care beds and represents a commercial opportunity exceeding USD $100 million annually. The FDA De Novo classification also supports accelerated approval pathways for PainChek's expansion into other US market segments, notably home care and hospitals, which are estimated to take the total US aged care market opportunity to $582 million. PainChek is strongly positioned for immediate commercial rollout in the US, bolstered by strategic partnerships with leading healthcare software providers PointClickCare and Eldermark. The FDA De Novo classification and new product code SGB also substantially increase the potential for expedited regulatory approval in Japan, the second-largest global market for long-term care, and other global markets that accept FDA approval.
PainChek's initial addressable market in US aged care comprises over 3 million long-term care beds and represents a commercial opportunity exceeding USD $100 million annually. The total US aged care market opportunity is estimated to be $582 million, including home care and hospitals.
PainChek is strongly positioned for immediate commercial rollout in the US, bolstered by strategic partnerships with leading healthcare software providers. The FDA De Novo classification and new product code SGB also substantially increase the potential for expedited regulatory approval in Japan and other global markets.